JP2021519295A5 - - Google Patents
Info
- Publication number
- JP2021519295A5 JP2021519295A5 JP2020551797A JP2020551797A JP2021519295A5 JP 2021519295 A5 JP2021519295 A5 JP 2021519295A5 JP 2020551797 A JP2020551797 A JP 2020551797A JP 2020551797 A JP2020551797 A JP 2020551797A JP 2021519295 A5 JP2021519295 A5 JP 2021519295A5
- Authority
- JP
- Japan
- Prior art keywords
- less
- milligrams
- antibody
- seq
- amino acid
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023218600A JP2024045121A (ja) | 2018-03-28 | 2023-12-25 | 抗ｃｄ３８抗体の皮下投薬 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862649489P | 2018-03-28 | 2018-03-28 | |
| US62/649,489 | 2018-03-28 | ||
| PCT/IB2019/000314 WO2019186273A1 (en) | 2018-03-28 | 2019-03-27 | Subcutaneous dosing of anti-cd38 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023218600A Division JP2024045121A (ja) | 2018-03-28 | 2023-12-25 | 抗ｃｄ３８抗体の皮下投薬 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021519295A JP2021519295A (ja) | 2021-08-10 |
| JPWO2019186273A5 JPWO2019186273A5 (https=) | 2022-03-23 |
| JP2021519295A5 true JP2021519295A5 (https=) | 2022-03-23 |
| JP7526099B2 JP7526099B2 (ja) | 2024-07-31 |
Family
ID=66647425
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551797A Active JP7526099B2 (ja) | 2018-03-28 | 2019-03-27 | 抗ｃｄ３８抗体の皮下投薬 |
| JP2023218600A Pending JP2024045121A (ja) | 2018-03-28 | 2023-12-25 | 抗ｃｄ３８抗体の皮下投薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023218600A Pending JP2024045121A (ja) | 2018-03-28 | 2023-12-25 | 抗ｃｄ３８抗体の皮下投薬 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210047427A1 (https=) |
| EP (1) | EP3774915A1 (https=) |
| JP (2) | JP7526099B2 (https=) |
| KR (2) | KR20250117714A (https=) |
| CN (1) | CN112154156A (https=) |
| AU (2) | AU2019244478B2 (https=) |
| BR (1) | BR112020019710A2 (https=) |
| CA (1) | CA3095086A1 (https=) |
| CO (1) | CO2020013252A2 (https=) |
| MX (1) | MX2020010144A (https=) |
| TW (2) | TWI847979B (https=) |
| WO (1) | WO2019186273A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| AU2015358615B2 (en) | 2014-12-04 | 2021-08-05 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute myeloid leukemia |
| MX389805B (es) | 2015-05-20 | 2025-03-11 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38. |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| DK3827845T3 (da) | 2015-11-03 | 2022-05-23 | Janssen Biotech Inc | Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf |
| JP2019527678A (ja) | 2016-06-28 | 2019-10-03 | ユーエムセー・ユトレヒト・ホールディング・ベー・フェー | ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療 |
| JP2021502961A (ja) | 2017-10-31 | 2021-02-04 | ヤンセン バイオテツク，インコーポレーテツド | 高リスク多発性骨髄腫の治療方法 |
| CA3111651A1 (en) * | 2018-09-11 | 2020-03-19 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-cd38 antibody, antigen-binding fragment thereof, and pharmaceutical use |
| WO2020081881A2 (en) * | 2018-10-17 | 2020-04-23 | Janssen Biotech, Inc. | Method of providing subcutaneous administration of anti-cd38 antibodies |
| MX2022006882A (es) * | 2019-12-05 | 2022-11-08 | Sanofi Aventis Us Llc | Formulaciones de anticuerpos anti-cd38 para administracion subcutanea. |
| BR112022023137A2 (pt) * | 2020-05-15 | 2023-02-07 | Takeda Pharmaceuticals Co | Administração de inibidor de enzima de ativação de sumo e anticorpos anti-cd38 |
| WO2023010031A1 (en) | 2021-07-28 | 2023-02-02 | Genentech, Inc. | Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of blood cancers |
| WO2023045859A1 (zh) * | 2021-09-23 | 2023-03-30 | 非同（成都）生物科技有限公司 | Cd38单克隆抗体及其应用 |
| WO2024131849A1 (zh) * | 2022-12-21 | 2024-06-27 | 非同（成都）生物科技有限公司 | Cd38单克隆抗体及其应用 |
| CN121127494A (zh) | 2023-01-06 | 2025-12-12 | 武田药品工业株式会社 | 用于治疗自身免疫性疾病的抗cd38抗体 |
| WO2025193746A1 (en) | 2024-03-12 | 2025-09-18 | Takeda Pharmaceutical Company Limited | Dosing regimens of anti-cd38 antibodies for treatment of subjects with immune thrombocytopenia |
| WO2025235919A1 (en) | 2024-05-09 | 2025-11-13 | Takeda Pharmaceutical Company Limited | Dosing regimens of anti-cd38 antibodies for treatment of subjects with immunoglobulin a nephropathy |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| IT1320715B1 (it) | 2000-10-19 | 2003-12-10 | Cselt Centro Studi Lab Telecom | Modulo generatore di circuiti per la decodifica di codiciconvoluzionali, metodo per la generazione di tale tipo di circuito e |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| EP1411851B1 (en) | 2001-08-03 | 2006-11-02 | Tyco Healthcare Group LP | Marker for use with a tissue marking apparatus |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| EP2567976B1 (en) * | 2005-03-23 | 2017-07-19 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| TW200745162A (en) | 2005-05-24 | 2007-12-16 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 |
| WO2007041635A2 (en) | 2005-10-03 | 2007-04-12 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| SG10201803288RA (en) | 2013-10-31 | 2018-05-30 | Sanofi Sa | Specific anti-cd38 antibodies for treating human cancers |
| PT3294769T (pt) | 2015-05-13 | 2021-04-13 | Morphosys Ag | Tratamento para mieloma múltiplo (mm) |
| DK3827845T3 (da) * | 2015-11-03 | 2022-05-23 | Janssen Biotech Inc | Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf |
| MA45674A (fr) * | 2016-07-15 | 2019-05-22 | Takeda Pharmaceuticals Co | Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes |
-
2019
- 2019-03-27 BR BR112020019710-6A patent/BR112020019710A2/pt unknown
- 2019-03-27 EP EP19726474.0A patent/EP3774915A1/en active Pending
- 2019-03-27 WO PCT/IB2019/000314 patent/WO2019186273A1/en not_active Ceased
- 2019-03-27 CA CA3095086A patent/CA3095086A1/en active Pending
- 2019-03-27 KR KR1020257024758A patent/KR20250117714A/ko active Pending
- 2019-03-27 MX MX2020010144A patent/MX2020010144A/es unknown
- 2019-03-27 AU AU2019244478A patent/AU2019244478B2/en active Active
- 2019-03-27 JP JP2020551797A patent/JP7526099B2/ja active Active
- 2019-03-27 US US17/041,783 patent/US20210047427A1/en active Pending
- 2019-03-27 KR KR1020207030604A patent/KR20210002499A/ko not_active Ceased
- 2019-03-27 CN CN201980032101.8A patent/CN112154156A/zh active Pending
- 2019-03-28 TW TW108110990A patent/TWI847979B/zh active
- 2019-03-28 TW TW113121338A patent/TW202504926A/zh unknown
-
2020
- 2020-10-22 CO CONC2020/0013252A patent/CO2020013252A2/es unknown
-
2023
- 2023-12-25 JP JP2023218600A patent/JP2024045121A/ja active Pending
-
2025
- 2025-10-29 AU AU2025259859A patent/AU2025259859A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021519295A5 (https=) | ||
| WO2019186273A4 (en) | Subcutaneous dosing of anti-cd38 antibodies | |
| JP2024045121A5 (https=) | ||
| JP2025016606A5 (https=) | ||
| JPWO2019186273A5 (https=) | ||
| JP2020528768A5 (https=) | ||
| JP2021528423A5 (https=) | ||
| JP2021524256A5 (https=) | ||
| CN108473578A (zh) | 治疗癌症的抗pd-1抗体和双特异性抗cd20/抗cd3抗体组合 | |
| JP2025032102A5 (https=) | ||
| JP2020002172A5 (https=) | ||
| JP2021510736A5 (https=) | ||
| JP2009519257A5 (https=) | ||
| AU2021221287B2 (en) | Engineered anti-IL-2 antibodies | |
| JP2015500822A5 (https=) | ||
| JP2021512107A5 (https=) | ||
| JP2021510523A5 (https=) | ||
| JP2023133432A5 (https=) | ||
| WO2013171287A1 (en) | Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide) | |
| US20240366597A1 (en) | Cancer treatment combinations | |
| JP2018533569A5 (https=) | ||
| JP2021506817A5 (https=) | ||
| CN116262135A (zh) | 抗cd27抗体组合物及其用途 | |
| JP2020533382A5 (https=) | ||
| JP2020533380A5 (https=) |